Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pelthos Therapeutics Inc. (PTHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nevada-incorporated biopharmaceutical company listed on the NYSE American, Pelthos files a range of documents with the U.S. Securities and Exchange Commission that describe its business, governance, and financial obligations.
Key filings include Form 8-K current reports, where Pelthos discloses material events such as financing transactions, product acquisitions, and governance changes. Recent 8-K filings describe a senior secured term loan facility with Horizon Technology Finance Corporation intended to support commercialization of ZELSUVMI and the launches of Xepi and Xeglyze, an asset purchase agreement for the Xeglyze head lice treatment, and a securities purchase agreement for senior secured convertible notes used to fund the acquisition and planned relaunch of Xepi and to accelerate ZELSUVMI commercialization.
Other 8-K items and the company’s definitive proxy statement on Schedule 14A provide detail on board composition, director compensation policies, annual meeting proposals, and shareholder voting results. These documents outline Pelthos’ governance structure, committee responsibilities, and the terms under which directors and executives are compensated and indemnified.
On Stock Titan, investors can review Pelthos’ periodic reports (such as Forms 10-K and 10-Q when filed) for information on revenue from ZELSUVMI, operating expenses, cash position, and risk factors related to its commercial dermatology portfolio and financing arrangements. Form 4 and related insider transaction reports, when available, show equity dealings by directors and officers, offering additional insight into insider alignment.
AI-driven summaries on this page highlight the most important points from lengthy filings, such as covenants in loan agreements, conversion terms in convertible notes, and implications of mergers and name changes. Real-time updates from EDGAR ensure that new Pelthos filings—whether related to financings, acquisitions, or governance—are quickly reflected, while the AI layer helps users understand how each document fits into the company’s broader strategy around ZELSUVMI, Xepi, and Xeglyze.
Pelthos Therapeutics Inc. is offering a resale prospectus covering up to 781,928 shares of its common stock. This includes 716,440 shares issuable upon conversion of secured convertible notes held by investors such as Ligand Pharmaceuticals, and 65,488 shares issuable upon exercise of warrants held by Horizon Technology Finance.
The shares may be sold from time to time by these selling stockholders using this shelf registration, and Pelthos will cover related registration expenses. Pelthos is a biopharmaceutical company commercializing ZELSUVMI, an FDA‑approved topical gel for molluscum contagiosum, launched in 2025.
The company highlights substantial risks, including a going concern qualification from its auditors and recurring net losses, with accumulated deficits of about $43.1 million as of September 30, 2025. Its ability to continue depends heavily on successfully commercializing ZELSUVMI and securing adequate capital.
Pelthos Therapeutics Inc. received an updated ownership report from investment entities 3i, LP, 3i Management LLC, and Maier Joshua Tarlow. They report beneficial ownership of 318,886 shares of common stock, representing 9.9% of the company’s outstanding shares based on 3,086,681 shares outstanding as of November 24, 2025.
The position includes 213,507 shares of common stock and 105,379 additional shares issuable from Series A convertible preferred stock and a senior secured convertible note, both subject to a 9.99% beneficial ownership blocker. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Pelthos Therapeutics.
Pelthos Therapeutics Inc. has filed a shelf registration to offer up to $200,000,000 of common stock, preferred stock, debt securities, warrants, rights and units from time to time. The company’s common stock trades on NYSE American under the symbol PTHS, with a public float of $39.2 million as of January 28, 2026, which limits primary equity sales under General Instruction I.B.6.
Pelthos is a biopharmaceutical company focused on commercializing ZELSUVMI, a berdazimer topical gel approved by the FDA in 2024 for molluscum contagiosum in patients one year and older. The business was formed through a 2025 merger involving Channel Therapeutics and LNHC, which holds rights to assets acquired from Novan.
The filing highlights substantial risks, including a going concern qualification on the 2024 and 2023 financial statements, an accumulated deficit of approximately $43.1 million as of September 30, 2025, continued net losses, and heavy dependence on the early-stage commercialization of ZELSUVMI. Additional risks span reimbursement, competition, manufacturing reliability, supply chain, third-party dependencies and intellectual property rights.
Pelthos Therapeutics Inc. entered into a venture loan and security agreement with Horizon Technology Finance, providing a senior secured term loan facility of up to $50.0 million. The company drew $30.0 million at closing, with up to an additional $20.0 million available upon achieving specified milestones, to support commercialization of ZELSUVMI, launches of Xepi and Xeglyze, and general corporate purposes.
The loans bear interest at the prime rate plus 3.75%, with the prime rate floored at 6.75%, and include an interest-only period through at least February 1, 2029, potentially extended to February 1, 2030 if trailing twelve-month consolidated net revenue reaches $75.0 million. The facility matures on January 31, 2031 and is secured by substantially all borrower assets. As part of the financing, Pelthos issued Horizon warrants to purchase 65,488 common shares at an exercise price of $27.49 per share, exercisable for five years.
Pelthos Therapeutics Inc. updated how it pays its non-employee directors, following a review by its compensation committee and approval by the board. Effective January 1, 2026, board members receive an annual cash retainer of $40,000, while the non-executive chairman receives $60,000. Committee retainers include $7,000 for audit committee members and $19,000 for the audit chair, $5,000 for compensation committee members and $15,000 for its chair, and $4,000 for nominating and corporate governance committee members and $12,000 for its chair.
The company notes that non-employee directors may receive an initial equity grant under its 2023 Equity Incentive Plan when they first join the board, at the board’s discretion, but they do not receive annual equity awards for ongoing service. Pelthos also furnished, but did not file, an investor presentation on its website as of January 12, 2026, highlighting that this information is provided under Regulation FD and is not incorporated into other securities filings unless specifically referenced.
Pelthos Therapeutics Inc. entered into an Asset Purchase Agreement with Hatchtech Pty Ltd under which Pelthos bought all rights to the Xeglyze Product, a head lice treatment using Abametapir, and related intellectual property, regulatory materials, and tangible assets. The aggregate purchase price is $1,800,000, consisting of a $450,000 down payment made on November 20, 2025 and a $1,350,000 cash payment made on December 23, 2025. Pelthos obtained contractual rights to claw back up to 100% of the purchase price for certain seller defaults and if closing had not occurred by December 29, 2025. The transaction was consummated on the agreed closing date, and Pelthos plans to issue a press release announcing the closing.
Pelthos Therapeutics Inc. reported an equity compensation grant to director Andrew J. Einhorn. On December 23, 2025, he was awarded 12,000 Restricted Stock Units (RSUs) of Pelthos common stock under the company’s 2023 Equity Incentive Plan, as amended and restated effective April 16, 2025. Each RSU represents a contingent right to receive one share of common stock with a par value of $0.0001 per share. The RSUs are scheduled to vest on January 1, 2027, meaning the shares will be delivered only if the vesting conditions tied to board service are satisfied.
Pelthos Therapeutics Inc. insider reporting shows that director Andrew J. Einhorn filed an initial ownership statement for the company’s stock. The filing is dated for an event on 12/23/2025 and confirms his status as a director of Pelthos Therapeutics Inc. (ticker PTHS).
In this Form 3, Einhorn reports that he has no securities beneficially owned in Pelthos Therapeutics Inc. as of the event date. The filing is made by a single reporting person and indicates that there are no non-derivative or derivative equity holdings currently attributed to him.
Pelthos Therapeutics Inc. expanded its Board of Directors from seven to eight members and appointed Andrew J. Einhorn as a new independent director. Einhorn, an experienced biotech and pharmaceutical finance executive, will serve until the company’s 2026 annual meeting of shareholders. Effective December 23, 2025, he joined the Audit Committee and the Compensation Committee. For his board service, he will receive standard non-employee director compensation and an equity grant of 12,000 restricted stock units, each representing one share of common stock, which will vest on January 1, 2027. The company also entered into a standard indemnification agreement with him and issued a press release announcing his appointment.